These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 29223415)

  • 1. [Psychological impact of prostate cancer on patients receiving a 6-month androgen deprivation therapy].
    de la Taille A; Mardoyan S; Lafaye A
    Prog Urol; 2018 Jan; 28(1):32-38. PubMed ID: 29223415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The role of a 6-month depot form of hormone therapy in the treatment of advanced hormone-dependent prostate cancer: Results from the 'ELIRE' observational study].
    Ouzaid I; Rouprêt M
    Prog Urol; 2011 Nov; 21(12):866-74. PubMed ID: 22035913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A longitudinal study on the impact of active surveillance for prostate cancer on anxiety and distress levels.
    Venderbos LD; van den Bergh RC; Roobol MJ; Schröder FH; Essink-Bot ML; Bangma CH; Steyerberg EW; Korfage IJ
    Psychooncology; 2015 Mar; 24(3):348-54. PubMed ID: 25138075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial.
    Denham JW; Wilcox C; Joseph D; Spry NA; Lamb DS; Tai KH; Matthews J; Atkinson C; Turner S; Christie D; Gogna NK; Kenny L; Duchesne G; Delahunt B; McElduff P
    Lancet Oncol; 2012 Dec; 13(12):1260-70. PubMed ID: 23151431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Quality of life following endocrine therapy for advanced prostate cancer: a comparative study between LH-RH agonist 1-month depot and 3-month depot].
    Namiki S; Ishidoya S; Saito S; Mitsukawa S; Suzuki Y; Numata I; Arai Y
    Nihon Hinyokika Gakkai Zasshi; 2008 Jul; 99(5):631-7. PubMed ID: 18697469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health-Related Quality of Life in 536 Long-Term Prostate Cancer Survivors after Treatment with Leuprorelin Acetate: A Combined Retrospective and Prospective Analysis.
    Hammerer PG; Wirth MP;
    Urol Int; 2018; 100(1):72-78. PubMed ID: 29183006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of LH-RH analogue 1-month depot and 3-month depot by their hormone levels and pharmacokinetic profile in patients with advanced prostate cancer.
    Tunn UW; Bargelloni U; Cosciani S; Fiaccavento G; Guazzieri S; Pagano F
    Urol Int; 1998; 60 Suppl 1():9-16; discussion 16-7. PubMed ID: 9563139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II, randomised, double-blind, placebo-controlled trial of methylphenidate for reduction of fatigue levels in patients with prostate cancer receiving LHRH-agonist therapy.
    Richard PO; Fleshner NE; Bhatt JR; Hersey KM; Chahin R; Alibhai SM
    BJU Int; 2015 Nov; 116(5):744-52. PubMed ID: 24684534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The current status of hormone treatment for prostate cancer patients in Korean real-world practice: a multi-institutional observational study.
    Kim JK; Kim JJ; Gang TW; Kwon TK; Kim HS; Park SC; Park JS; Park JY; Yoon SJ; Jeon YS; Cho JS; Joo KJ; Hong SH; Byun SS;
    Asian J Androl; 2019; 21(2):115-120. PubMed ID: 30604695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost analysis of leuprorelin acetate in Japanese prostate cancer patients: comparison between 6-month and 3-month depot formulations.
    Goto R; Uda A; Hiroi S; Iwasaki K; Takashima K; Oya M
    J Med Econ; 2017 Nov; 20(11):1155-1162. PubMed ID: 28758810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical study results of the new formulation leuprorelin acetate three-month depot for the treatment of advanced prostate carcinoma.
    Fornara P; Jocham D
    Urol Int; 1996; 56 Suppl 1():18-22. PubMed ID: 8776813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the association of prostate cancer-specific anxiety with sexual function, depression and cancer aggressiveness in men 1 year following surgical treatment for localized prostate cancer.
    Tavlarides AM; Ames SC; Diehl NN; Joseph RW; Castle EP; Thiel DD; Broderick GA; Parker AS
    Psychooncology; 2013 Jun; 22(6):1328-35. PubMed ID: 22855322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between illness uncertainty, anxiety, fear of progression and quality of life in men with favourable-risk prostate cancer undergoing active surveillance.
    Parker PA; Davis JW; Latini DM; Baum G; Wang X; Ward JF; Kuban D; Frank SJ; Lee AK; Logothetis CJ; Kim J
    BJU Int; 2016 Mar; 117(3):469-77. PubMed ID: 25714186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of long-term androgen deprivation therapy on penile length in patients with prostate cancer: a single-center, prospective, open-label, observational study.
    Park KK; Lee SH; Chung BH
    J Sex Med; 2011 Nov; 8(11):3214-9. PubMed ID: 21699669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study.
    Potosky AL; Knopf K; Clegg LX; Albertsen PC; Stanford JL; Hamilton AS; Gilliland FD; Eley JW; Stephenson RA; Hoffman RM
    J Clin Oncol; 2001 Sep; 19(17):3750-7. PubMed ID: 11533098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unusual side effect from a luteinizing hormone-releasing hormone agonist, leuprorelin, in the treatment of prostate cancer: a case report.
    Chang JI; Bucci J
    J Med Case Rep; 2016 Nov; 10(1):323. PubMed ID: 27836000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Total androgen blockade versus a luteinizing hormone-releasing hormone agonist alone in men with high-risk prostate cancer treated with radiotherapy.
    Nanda A; Chen MH; Moran BJ; Braccioforte MH; Dosoretz D; Salenius S; Katin M; Ross R; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2010 Apr; 76(5):1439-44. PubMed ID: 19540066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between hot flashes and distress in men receiving androgen deprivation therapy for prostate cancer.
    Ulloa EW; Salup R; Patterson SG; Jacobsen PB
    Psychooncology; 2009 Jun; 18(6):598-605. PubMed ID: 18942660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular Mortality Following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08.
    Voog JC; Paulus R; Shipley WU; Smith MR; McGowan DG; Jones CU; Bahary JP; Zeitzer KL; Souhami L; Leibenhaut MH; Rotman M; Husain SM; Gore E; Raben A; Chafe S; Sandler HM; Efstathiou JA
    Eur Urol; 2016 Feb; 69(2):204-10. PubMed ID: 26362090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient anxiety about prostate cancer independently predicts early initiation of androgen deprivation therapy for biochemical cancer recurrence in older men: a prospective cohort study.
    Dale W; Hemmerich J; Bylow K; Mohile S; Mullaney M; Stadler WM
    J Clin Oncol; 2009 Apr; 27(10):1557-63. PubMed ID: 19255325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.